Skip to Main Content

Webinar

Webinar: InVitria + Evonik

Article · Published 2026-09-16 · 1 min read

From Cell Banking to Cell Therapy: The Role of Recombinant Albumin in Cryopreservation

November 10, 2026 | 9:00 a.m. EST / 3:00 p.m. CET

How Evonik and InVitria® are enabling animal component-free, scalable cell therapy manufacturing with next-generation rHSA solutions

Cryopreservation is a critical step in cell therapy manufacturing, and it remains exposed to raw material variability, supply constraints, and concerns about animal- or human-derived components.

In this live webinar, Evonik and InVitria will share application data showing how recombinant human serum albumin (rHSA) supports consistent, animal component-free cryopreservation of iPSCs, T cells, and MSCs. The session will also cover how rHSA compares with plasma-derived albumin and what to consider when evaluating recombinant albumin for GMP manufacturing.

From Cell Banking to Cell Therapy webinar on the role of recombinant albumin in cryopreservation, November 10, 2026, presented by Evonik and InVitria

Why Attend This Webinar?

  • Understand how animal component-free rHSA can reduce variability and support more defined cell therapy manufacturing workflows.
  • See how rHSA performs in iPSC, T cell, and MSC cryopreservation models, including post-thaw outcomes beyond viability.
  • Learn how recombinant albumin compares with plasma-derived albumin in purity, consistency, and supply security.
  • Get practical guidance on evaluating rHSA for GMP workflows, including formulation fit, qualification, comparability, and closed-system integration.
Where cryopreservation fits in cell therapy manufacturing: cell banking, expansion, final product and post-thaw

Featured Products

The session features Evonik’s CreaCyte® rHSA for biomanufacturing, powered by Optibumin® 25, InVitria’s ready-to-use 25% liquid recombinant albumin designed for biomanufacturing and closed-system workflows.

Meet the Speakers

Clea Michel, Evonik

Cléa Michel

Global Director Product Management, Biopharma Solutions | Evonik Health Care

Michel leads Evonik’s portfolio of ingredients and technologies for biopharmaceutical manufacturing, from transient protein expression and upstream media optimization to downstream purification and drug product formulation. She draws on a background in biochemistry and biotechnology to help biopharma companies improve process performance.

Mark Stathos, InVitria

Dr. Mark Stathos

Director, Cell Biology | InVitria

Dr. Stathos leads InVitria’s Cell Biology lab, producing application notes and publications on how InVitria products perform in industrially relevant applications such as cell and gene therapy manufacturing. He has more than a decade of hands-on cell culture experience and holds a PhD in Bioengineering from Georgia Tech.

Jake Hanks, InVitria

Jake Hanks

Director, Business Development | InVitria

Hanks supports InVitria’s key accounts, building strategic partnerships that guide customers through evaluation, qualification, regulatory approval, and scale-up. He holds a BS and an MBA from the University of Tulsa.

Reserve Your Spot

Registration is hosted by Evonik.

CreaCyte® is a registered trademark of Evonik. Optibumin® is a registered trademark of InVitria.

More resources

Keep reading.

Talk to a Scientist

See how rHSA performs in your media.

Send us your cell line and formulation and we will help you design a side-by-side evaluation against your current albumin.